Karyopharm Therapeutics Inc (USD)
KPTI
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range16.00 | 17.00
52-Wk Range- | -
Last Close16.99
Mkt Cap (m)1,250.48
Dividend yield-
ISINUS48576U1060
Volume23,349.00
Exchange VenueNAS

Company Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.

Key Information
Price/Earning-
Price/Book14.93
Price/Sales12.98
P/CF-
Rev Growth (3 year avg)542.75
EPS Growth (3 year avg)-
Operating Margin % -462.85
Net Margin %-488.08
Return on Equity-171.36
Debt/Equity2.51

Documents

Prospectus
en 05/05/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.karyopharm.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)0.230.250.151.6130.3440.89
Operating Income (m)-75.85-119.08-110.73-130.54-179.88-189.28
Net Income (m)-75.78-118.18-109.58-128.98-178.41-199.59
Basic EPS-2.43-3.32-2.92-2.81-3.14-3.22
Avg. Diluted Shares Outstanding (m)31.1435.6237.5245.9056.8061.96
Balance Sheet
USD201420152016201720182019
Current Assets (m)207.75177.60131.64148.42334.61278.57
Non Current Assets (m)12.5937.8448.7531.876.5816.39
Total Assets (m)220.34215.44180.39180.29341.19294.96
Current Liabilities (m)12.3015.1316.4849.4746.9046.35
Total Liabilities (m)------
Total Equity (m)206.79198.37162.24129.46183.1749.77
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-51.45-94.03-84.39-73.72-159.12-190.82
Capital Expenditure (m)-2.83-1.42-0.07-0.06-2.36-0.21
Figures are quoted in USD unless stated otherwise
-
No change
$
16.99
Last Price